Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Robert J. Bonczek | - | - |
Cellective BioTherapy, Inc.
 Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | - |
| Fred Eshelman | M | 76 |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | 8 anni |
| Robert R. Bonczek | M | - |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Daniel Janney | M | 58 |
Cellective Therapeutics, Inc.
 Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | - |
| Wayne T. Hockmeyer | M | 79 |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | - |
| James Healy | M | 59 |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | - |
| Louis C. Bock | M | 59 |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | - |
| Garheng Kong | M | 49 |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | 2 anni |
| Jeanne M. Riley | F | - |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | 4 anni |
| David M. Hilbert | M | - |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | 4 anni |
| Fazal R. Khan | M | 74 |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | - |
| Alter E. Geller | M | - |
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | 5 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 12 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Thomas F. Tedder
- Contatti personali
